








PRODUCT	INDICATION/PHASE	PARTNERS
---------	------------------	----------


## COVID-19

INO-4800	COVID-19 (INNOVATE)* <div> <div></div> <div>PHASE 3</div> </div>	 <b>Advaccine</b> <small>BILL &amp; MELINDA GATES foundation</small>  <b>CEPI</b>
	COVID-19 (Solidarity) <div> <div></div> <div>PHASE 3</div> </div>	 <b>World Health Organization</b>



## INFECTIOUS DISEASES

INO-4700	MERS <div> <div></div> <div>PHASE 2</div> </div>	
INO-4500	Lassa Fever <div> <div></div> <div>PHASE 1</div> </div>	
INO-4201	Ebola (Booster) <div> <div></div> <div>PHASE 1</div> </div>	  <b>UNIVERSITÉ DE GENÈVE</b> <b>GuardRX</b>




## HPV-TARGETED

VGX-3100	Precancerous Cervical Dysplasia (HSIL) <div> <div></div> <div>PHASE 3</div> </div>	 <b>Apollobio</b>  (China; INOVIO maintains global rights)
	Precancerous Vulvar Dysplasia (HSIL) <div> <div></div> <div>COMPLETED PHASE 2</div> </div>	
	Precancerous Anal Dysplasia (HSIL) <div> <div></div> <div>COMPLETED PHASE 2</div> </div>	
INO-3107	Recurrent Respiratory Papillomatosis (RRP) <div> <div></div> <div>PHASE 2</div> </div>	

## IMMUNO-ONCOLOGY

INO-5401	Glioblastoma Multiforme (GBM) <div> <div></div> <div>PHASE 2</div> </div>	<b>REGENERON</b>
INO-5151	Prostate Cancer <div> <div></div> <div>PHASE 1</div> </div>	 <b>CANCER RESEARCH INSTITUTE</b>  <b>PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY</b>

## dMAb™

	COVID-19 <div> <div></div> <div>PRE-CLINICAL</div> </div>	<b>AstraZeneca</b>   
INO-A002	Zika <div> <div></div> <div>PHASE 1</div> </div>	<b>BILL &amp; MELINDA GATES foundation</b>

PRODUCT	INDICATION/PHASE	PARTNERS
---------	------------------	----------

\* Advaccine funding 50% of INNOVATE Phase 3 Clinical Trial